

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**Manuscript NO:** 62946

**Title:** Advances in Treatment and Prevention of Hepatitis B

**Reviewer's code:** 05420739

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-01-26

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-01-30 02:28

**Reviewer performed review:** 2021-02-15 04:22

**Review time:** 16 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

In the present manuscript, the authors summarized the new progress of HBV research after the publication of the AASLD 2018 Hepatitis B Guidance by searched the HBV related literatures within the last three years. I have several comments list below. 1.

For the title “Advances in treatment and prevention of Hepatitis B”, the new progress in present manuscript was mainly focused on the advances for the AASLD 2018 Hepatitis B Guidance. However, there are some other HBV-related guides, such as EASL 2017 Guidelines and APASL 2019 Guidelines. The contents of these guides are not exactly the same, thus the topic does not fully reflect the main subject of the manuscript.

2. For the markers HBV testing, such as cccDNA, HBcrAg and HBV RNA, which have been studied for a long time, but they were not mentioned in the AASLD 2018 Hepatitis B Guidance. This is because these biomarkers have their limitations which have not been completely resolved, thus authors should fully discuss. 3. For Hepatitis B vaccination strategies, the prevention of mother-to-child transmission (MTCT) for HBV is key to reducing the global burden of chronic hepatitis B. Concurrent use of hepatitis B immunoglobulin and hepatitis B vaccine has substantially reduced the MTCT of HBV, nearly zero infection in children of carrier mother with negative HBeAg and 5-10% infection in children of HBeAg-positive mothers. Through improved immune strategies and antiviral treatment in HBeAg-positive mothers, the infection rate of MTCT of HBV can be reduced to less than 1%. The authors should highlight the efficacy and barriers of the currently validated measures for the prevention of HBV MTCT. 4. In the AASLD 2018 Hepatitis B Guidance, immune-Tolerant CHB do not be recommended for treatment. However, in the present manuscript immune-tolerant (HBeAg positive) CHB patients were also received TDF and/or Emtricitabine, does this mean a change in the antiviral therapy?

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**Manuscript NO:** 62946

**Title:** Advances in Treatment and Prevention of Hepatitis B

**Reviewer's code:** 05420739

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-01-26

**Reviewer chosen by:** Jia-Ru Fan

**Reviewer accepted review:** 2021-03-24 00:10

**Reviewer performed review:** 2021-03-24 00:31

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

No comment. I accept the author's revision of the manuscript.